FIGURE 1.

Evaluation of AXL and p53 expression in relation to the clinical outcomes of osimertinib treatment in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) tumors. (A) AXL and p53 expression levels in tumors from patients with EGFR‐mutated NSCLC. (B,C) Kaplan–Meier survival curves for (B) progression‐free survival (PFS) and (C) overall survival (OS) of EGFR‐mutated NSCLC patients receiving osimertinib treatment between the low and high AXL expression groups, and negative and positive p53 expression groups. CI, confidence interval; HR, hazard ratio; NE, not evaluable